Skip to main content
Erschienen in: Osteoporosis International 2/2017

31.08.2016 | Original Article

Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model

verfasst von: W. Ni, Y. Jiang

Erschienen in: Osteoporosis International | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Summary

This study used a simulation model to determine the cost-effective threshold of fracture risk to treat osteoporosis among elderly Chinese women. Osteoporosis treatment is cost-effective among average-risk women who are at least 75 years old and above-average-risk women who are younger than 75 years old.

Introduction

Aging of the Chinese population is imposing increasing economic burden of osteoporosis. This study evaluated the cost-effectiveness of osteoporosis treatment among the senior Chinese women population.

Methods

A discrete event simulation model using age-specific probabilities of hip fracture, clinical vertebral fracture, wrist fracture, humerus fracture, and other fracture; costs (2015 US dollars); and quality-adjusted life years (QALYs) was used to assess the cost-effectiveness of osteoporosis treatment. Incremental cost-effectiveness ratio (ICER) was calculated. The willingness to pay (WTP) for a QALY in China was compared with the calculated ICER to decide the cost-effectiveness. To determine the absolute 10-year hip fracture probability at which the osteoporosis treatment became cost-effective, average age-specific probabilities for all fractures were multiplied by a relative risk (RR) that was systematically varied from 0 to 10 until the WTP threshold was observed for treatment relative to no intervention. Sensitivity analyses were also performed to evaluate the impacts from WTP and annual treatment costs.

Results

In baseline analysis, simulated ICERs were higher than the WTP threshold among Chinese women younger than 75, but much lower than the WTP among the older population. Sensitivity analyses indicated that cost-effectiveness could vary due to a higher WTP threshold or a lower annual treatment cost. A 30 % increase in WTP or a 30 % reduction in annual treatment costs will make osteoporosis treatment cost-effective for Chinese women population from 55 to 85.

Conclusions

The current study provides evidence that osteoporosis treatment is cost-effective among a subpopulation of Chinese senior women. The results also indicate that the cost-effectiveness of using osteoporosis treatment is sensitive to the WTP threshold and annual treatment costs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581–589CrossRefPubMed Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581–589CrossRefPubMed
2.
Zurück zum Zitat Kanis JA, Black D, Cooper C, et al. (2002) A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13:527–536CrossRefPubMed Kanis JA, Black D, Cooper C, et al. (2002) A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13:527–536CrossRefPubMed
3.
Zurück zum Zitat 1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. Osteoporos Int 8(Suppl 4):S7–80 1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. Osteoporos Int 8(Suppl 4):S7–80
4.
Zurück zum Zitat Jiang Y, Ni W (2015) Expected lifetime numbers, risks, and burden of osteoporotic fractures for 50-year old Chinese women: a discrete event simulation incorporating FRAX. J Bone Miner Metab Jiang Y, Ni W (2015) Expected lifetime numbers, risks, and burden of osteoporotic fractures for 50-year old Chinese women: a discrete event simulation incorporating FRAX. J Bone Miner Metab
5.
Zurück zum Zitat Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936CrossRefPubMed Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936CrossRefPubMed
6.
Zurück zum Zitat Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767CrossRefPubMed Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767CrossRefPubMed
7.
Zurück zum Zitat Liang H, ZHONG W, Ning L (2009) Statistics on the expenses for medical care of osteoporotic fractures in Beijing Jishuitan Hospital (from 2000 to 2006)[J]. Journal of Practical Orthopaedics 5:000 Liang H, ZHONG W, Ning L (2009) Statistics on the expenses for medical care of osteoporotic fractures in Beijing Jishuitan Hospital (from 2000 to 2006)[J]. Journal of Practical Orthopaedics 5:000
8.
Zurück zum Zitat Mithal A, Ebeling P, Kyer C (2013) The Asia-Pacific regional audit: epidemiology, costs, and burden of osteoporosis in 2013. International osteoporosis foundation Mithal A, Ebeling P, Kyer C (2013) The Asia-Pacific regional audit: epidemiology, costs, and burden of osteoporosis in 2013. International osteoporosis foundation
9.
Zurück zum Zitat Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473CrossRefPubMed Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473CrossRefPubMed
10.
Zurück zum Zitat Hasegawa Y, Suzuki S, Wingstrand H (2007) Risk of mortality following hip fracture in Japan. J Orthop Sci 12:113–117CrossRefPubMed Hasegawa Y, Suzuki S, Wingstrand H (2007) Risk of mortality following hip fracture in Japan. J Orthop Sci 12:113–117CrossRefPubMed
11.
Zurück zum Zitat Lips P, van Schoor NM (2005) Quality of life in patients with osteoporosis. Osteoporos Int 16:447–455CrossRefPubMed Lips P, van Schoor NM (2005) Quality of life in patients with osteoporosis. Osteoporos Int 16:447–455CrossRefPubMed
12.
Zurück zum Zitat Jansen JP, Bergman GJ, Huels J, Olson M (2011) The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 40(275–284):e271–e272 Jansen JP, Bergman GJ, Huels J, Olson M (2011) The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 40(275–284):e271–e272
13.
Zurück zum Zitat Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. PharmacoEconomics 21:305–314CrossRefPubMed Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. PharmacoEconomics 21:305–314CrossRefPubMed
14.
Zurück zum Zitat Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047–1061CrossRefPubMed Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047–1061CrossRefPubMed
15.
Zurück zum Zitat Zhang Z, Ou Y, Sheng Z, Liao E (2014) How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women. Endocrine 45:195–197CrossRefPubMed Zhang Z, Ou Y, Sheng Z, Liao E (2014) How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women. Endocrine 45:195–197CrossRefPubMed
16.
Zurück zum Zitat Bleibler F, Rapp K, Jaensch A, Becker C, Konig H-H (2014) Expected lifetime numbers and costs of fractures in postmenopausal women with and without osteoporosis in Germany: a discrete event simulation model. BMC Health Serv Res 14:284CrossRefPubMedPubMedCentral Bleibler F, Rapp K, Jaensch A, Becker C, Konig H-H (2014) Expected lifetime numbers and costs of fractures in postmenopausal women with and without osteoporosis in Germany: a discrete event simulation model. BMC Health Serv Res 14:284CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Caro JJ (2005) Pharmacoeconomic analyses using discrete event simulation. PharmacoEconomics 23:323–332CrossRefPubMed Caro JJ (2005) Pharmacoeconomic analyses using discrete event simulation. PharmacoEconomics 23:323–332CrossRefPubMed
18.
Zurück zum Zitat Kung AW, Lee KK, Ho AY, Tang G, Luk KD (2007) Ten-year risk of osteoporotic fractures in postmenopausal Chinese women according to clinical risk factors and BMD T-scores: a prospective study. J Bone Miner Res 22:1080–1087CrossRefPubMed Kung AW, Lee KK, Ho AY, Tang G, Luk KD (2007) Ten-year risk of osteoporotic fractures in postmenopausal Chinese women according to clinical risk factors and BMD T-scores: a prospective study. J Bone Miner Res 22:1080–1087CrossRefPubMed
19.
Zurück zum Zitat Hiligsmann M, Ethgen O, Bruyère O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12:687–696CrossRefPubMed Hiligsmann M, Ethgen O, Bruyère O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12:687–696CrossRefPubMed
20.
Zurück zum Zitat Borgström F (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495–505CrossRefPubMed Borgström F (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495–505CrossRefPubMed
21.
Zurück zum Zitat Borgström F, Ström O, Kleman M, McCloskey E, Johansson H, Odén A, Kanis J (2011) Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. Osteoporos Int 22:955–965CrossRefPubMed Borgström F, Ström O, Kleman M, McCloskey E, Johansson H, Odén A, Kanis J (2011) Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. Osteoporos Int 22:955–965CrossRefPubMed
22.
Zurück zum Zitat Kim K, Svedbom A, Luo X, Sutradhar S, Kanis J (2014) Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporos Int 25:325–337CrossRefPubMed Kim K, Svedbom A, Luo X, Sutradhar S, Kanis J (2014) Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporos Int 25:325–337CrossRefPubMed
23.
Zurück zum Zitat Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA, Manitoba Bone Density P (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 27:1243–1251CrossRefPubMed Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA, Manitoba Bone Density P (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 27:1243–1251CrossRefPubMed
24.
Zurück zum Zitat Liao E-Y, Wu X-P, Deng X-G, Huang G, Zhu X-P, Long Z-F, Wang W-B, Tang W-L, Zhang H (2002) Age-related bone mineral density, accumulated bone loss rate and prevalence of osteoporosis at multiple skeletal sites in Chinese women. Osteoporos Int 13:669–676CrossRefPubMed Liao E-Y, Wu X-P, Deng X-G, Huang G, Zhu X-P, Long Z-F, Wang W-B, Tang W-L, Zhang H (2002) Age-related bone mineral density, accumulated bone loss rate and prevalence of osteoporosis at multiple skeletal sites in Chinese women. Osteoporos Int 13:669–676CrossRefPubMed
25.
Zurück zum Zitat Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP (1982) A convenient approximation of life expectancy (the “DEALE”): II. Use in medical decision-making The American journal of medicine 73:889–897PubMed Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP (1982) A convenient approximation of life expectancy (the “DEALE”): II. Use in medical decision-making The American journal of medicine 73:889–897PubMed
26.
Zurück zum Zitat Fang X, Shi J, Song X, Mitnitski A, Tang Z, Wang C, Yu P, Rockwood K (2012) Frailty in relation to the risk of falls, fractures, and mortality in older Chinese adults: results from the Beijing Longitudinal Study of Aging. J Nutr Health Aging 16:903–907CrossRefPubMed Fang X, Shi J, Song X, Mitnitski A, Tang Z, Wang C, Yu P, Rockwood K (2012) Frailty in relation to the risk of falls, fractures, and mortality in older Chinese adults: results from the Beijing Longitudinal Study of Aging. J Nutr Health Aging 16:903–907CrossRefPubMed
28.
Zurück zum Zitat Wang C-B, Lin C-FJ, Liang W-M, Cheng C-F, Chang Y-J, Wu H-C, Wu T-N, Leu T-H (2013) Excess mortality after hip fracture among the elderly in Taiwan: a nationwide population-based cohort study. Bone 56:147–153CrossRefPubMed Wang C-B, Lin C-FJ, Liang W-M, Cheng C-F, Chang Y-J, Wu H-C, Wu T-N, Leu T-H (2013) Excess mortality after hip fracture among the elderly in Taiwan: a nationwide population-based cohort study. Bone 56:147–153CrossRefPubMed
29.
Zurück zum Zitat Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108–112CrossRefPubMed Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108–112CrossRefPubMed
30.
Zurück zum Zitat Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521CrossRefPubMed Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521CrossRefPubMed
31.
Zurück zum Zitat Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL, National Osteoporosis Foundation Guide C (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447CrossRefPubMedPubMedCentral Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL, National Osteoporosis Foundation Guide C (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Hwang JS, Chin LS, Chen JF, Yang TS, Chen PQ, Tsai KS, Leung PC (2011) The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. J Bone Miner Metab 29:328–333CrossRefPubMed Hwang JS, Chin LS, Chen JF, Yang TS, Chen PQ, Tsai KS, Leung PC (2011) The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. J Bone Miner Metab 29:328–333CrossRefPubMed
33.
Zurück zum Zitat Sun S, Chen J, Johannesson M, Kind P, Xu L, Zhang Y, Burström K (2011) Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008. Qual Life Res 20:309–320CrossRefPubMed Sun S, Chen J, Johannesson M, Kind P, Xu L, Zhang Y, Burström K (2011) Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008. Qual Life Res 20:309–320CrossRefPubMed
35.
Zurück zum Zitat Qu B, Ma Y, Yan M, Wu H-H, Fan L, Liao D-F, Pan X-M, Hong Z (2014) The economic burden of fracture patients with osteoporosis in western China. Osteoporos Int 25:1853–1860CrossRefPubMed Qu B, Ma Y, Yan M, Wu H-H, Fan L, Liao D-F, Pan X-M, Hong Z (2014) The economic burden of fracture patients with osteoporosis in western China. Osteoporos Int 25:1853–1860CrossRefPubMed
36.
Zurück zum Zitat Shih V, Chan A, Xie F, Ko Y (2012) Health state utility assessment for breast cancer. Value in Health Regional Issues 1:93–97CrossRef Shih V, Chan A, Xie F, Ko Y (2012) Health state utility assessment for breast cancer. Value in Health Regional Issues 1:93–97CrossRef
37.
Zurück zum Zitat Hagino H, Nakamura T, Fujiwara S, Oeki M, Okano T, Teshima R (2009) Sequential change in quality of life for patients with incident clinical fractures: a prospective study. Osteoporos Int 20:695–702CrossRefPubMed Hagino H, Nakamura T, Fujiwara S, Oeki M, Okano T, Teshima R (2009) Sequential change in quality of life for patients with incident clinical fractures: a prospective study. Osteoporos Int 20:695–702CrossRefPubMed
41.
Zurück zum Zitat Zhao F-L, Yue M, Yang H, Wang T, Wu J-H, Li S-C (2011) Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis. Med Care 49:267–272CrossRefPubMed Zhao F-L, Yue M, Yang H, Wang T, Wu J-H, Li S-C (2011) Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis. Med Care 49:267–272CrossRefPubMed
42.
Zurück zum Zitat Moriwaki K, Komaba H, Noto S, Yanagisawa S, Takiguchi T, Inoue H, Toujo T, Fukagawa M, Takahashi HE (2013) Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. J Bone Miner Res 28:395–403CrossRefPubMed Moriwaki K, Komaba H, Noto S, Yanagisawa S, Takiguchi T, Inoue H, Toujo T, Fukagawa M, Takahashi HE (2013) Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. J Bone Miner Res 28:395–403CrossRefPubMed
43.
Zurück zum Zitat Kling JM, Clarke BL, Sandhu NP (2014) Osteoporosis prevention, screening, and treatment: a review. J Women’s Health (Larchmt) 23:563–572CrossRef Kling JM, Clarke BL, Sandhu NP (2014) Osteoporosis prevention, screening, and treatment: a review. J Women’s Health (Larchmt) 23:563–572CrossRef
44.
Zurück zum Zitat Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De Laet C, Jonsson B (2005) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16:6–14CrossRefPubMed Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De Laet C, Jonsson B (2005) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16:6–14CrossRefPubMed
45.
Zurück zum Zitat Caro JJ, Möller J, Getsios D (2010) Discrete event simulation: the preferred technique for health economic evaluations? Value Health 13:1056–1060CrossRefPubMed Caro JJ, Möller J, Getsios D (2010) Discrete event simulation: the preferred technique for health economic evaluations? Value Health 13:1056–1060CrossRefPubMed
46.
Zurück zum Zitat Van Gestel A, Severens JL, Webers CA, Beckers HJ, Jansonius NM, Schouten JS (2010) Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. Value Health 13:358–367CrossRefPubMed Van Gestel A, Severens JL, Webers CA, Beckers HJ, Jansonius NM, Schouten JS (2010) Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. Value Health 13:358–367CrossRefPubMed
Metadaten
Titel
Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model
verfasst von
W. Ni
Y. Jiang
Publikationsdatum
31.08.2016
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 2/2017
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3751-z

Weitere Artikel der Ausgabe 2/2017

Osteoporosis International 2/2017 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.